Scientific Research & Evidence
Peer-reviewed studies supporting the use of mesenchymal stem cells (MSCs) and umbilical cord-derived stem cells in regenerative medicine
Understanding the Science
The field of regenerative medicine has experienced remarkable growth over the past two decades, with mesenchymal stem cells (MSCs) emerging as one of the most promising therapeutic tools. Umbilical cord-derived MSCs, in particular, have demonstrated significant potential due to their unique properties and ethical sourcing.
Key Scientific Findings
- MSCs do not replace damaged tissue but work through paracrine signaling—secreting growth factors, cytokines, and extracellular vesicles that modulate inflammation and stimulate tissue repair
- Umbilical cord MSCs offer advantages over bone marrow-derived cells: painless collection, faster self-renewal, higher proliferation rates, and no ethical concerns
- Clinical trials have shown safety and efficacy across numerous conditions including osteoarthritis, rheumatoid arthritis, autoimmune disorders, and degenerative diseases
- Over 119 clinical trials using umbilical cord MSCs are registered on ClinicalTrials.gov
Expert Presentations: The Science of Stem Cells
Watch Dr. Neil Riordan, founder of the Stem Cell Institute in Panama, present comprehensive information about mesenchymal stem cells, their mechanisms of action, and clinical applications.
Additional Educational Videos
Q&A: Food Intolerances & Autoimmune Disorders
Dr. Riordan answers common questions about stem cell therapy for autoimmune conditions, food sensitivities, and long-term treatment outcomes.
Clinical Applications & Patient Outcomes
Learn about real patient outcomes, treatment protocols, and the science behind UC-MSC therapy for various conditions.
What Are Mesenchymal Stem Cells (MSCs)?
Mesenchymal stem cells are multipotent stromal cells capable of self-renewal and differentiation into various cell types. However, current research demonstrates that their therapeutic effects are primarily mediated through paracrine mechanisms rather than direct cell replacement.
How MSCs Work
Rather than becoming new tissue, MSCs function as “repair coordinators” by:
- Secreting Growth Factors: Including VEGF, TGF-β, PDGF, IGF, and IGFBP that promote tissue regeneration
- Releasing Anti-Inflammatory Cytokines: Such as IL-10, IL-1RA, TNF-RI, TNF-RII, and TIMP-1/TIMP-2 that reduce chronic inflammation
- Producing Extracellular Vesicles: Including exosomes containing RNA, proteins, and mitochondria that communicate with damaged cells
- Modulating Immune Response: Suppressing overactive immune cells while promoting regulatory T cells
A landmark 2008 study demonstrated this mechanism: when human umbilical cord MSCs were placed in a biodegradable gel at the site of severed rat spinal cords, the cords regenerated. However, analysis revealed that none of the human cells had become part of the nervous system—they remained between nerve fibers, secreting factors that stimulated natural repair.
Why Umbilical Cord MSCs?
Advantages of UC-MSCs
- Younger, More Potent Cells: Newborn MSCs divide every 24 hours in culture, compared to every 48 hours for middle-aged cells. This means exponentially more therapeutic capacity
- Superior Proliferation: Higher expansion capacity and differentiation potential compared to adult tissue-derived MSCs
- Low Immunogenicity: Can be used allogenically with minimal rejection risk
- Rich in Bioactive Factors: Contains high concentrations of growth factors, cytokines, hyaluronic acid, and extracellular vesicles
- Ethical Sourcing: Obtained from donated umbilical cord tissue after healthy births—no embryos or fetuses destroyed
- Quality Control: Allows for rigorous screening, testing, and selection of the most therapeutically effective cell populations
He, H., & Nagamura-Inoue, T. (2014). Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World Journal of Stem Cells, 6(2), 195-202. https://pmc.ncbi.nlm.nih.gov/articles/PMC3999777/
Wharton’s Jelly: The Source of UC-MSCs
Gupta, A., El-Amin, S. F., Levy, H. J., et al. (2020). PMID: 32054483
Clinical Evidence: Osteoarthritis & Joint Conditions
Clinical Evidence: Rheumatoid Arthritis & Autoimmune Conditions
Landmark Clinical Trial Results (2013)
Randomized controlled trial with 172 rheumatoid arthritis patients receiving 40 million UC-MSCs IV demonstrated:
- Zero serious adverse events
- 100% of patients showed improvement
- TNF-α (primary inflammatory cytokine) decreased by 50% after one treatment
- Second treatment at 3 months produced total 75% reduction in TNF-α
- Therapeutic effects persisted for at least 8 months
- IL-6 and other inflammatory markers remained suppressed throughout follow-up
Long-term outcomes: Many patients remain medication-free years after a single treatment. Some patients require retreatment, but rheumatoid arthritis consistently shows high response rates with UC-MSC therapy.
Comprehensive UC-MSC Research & Applications
Additional Clinical Applications
Safety Profile of UC-MSC Therapy
Established Safety Record
- Multiple large-scale clinical trials have demonstrated zero serious adverse events related to UC-MSC administration
- Most common side effects are mild and temporary: flu-like symptoms, minor injection site reactions, temporary fatigue
- Properly sourced, tested, and administered MSCs under medical oversight have a strong safety profile
- Donor screening, infectious disease testing, endotoxin testing, and quarantine protocols ensure product safety
- No evidence of tumor formation or ectopic tissue growth in properly manufactured UC-MSC products
Important Note: Safety is dependent on proper manufacturing, quality control, and medical oversight. Patients should seek treatment from facilities with established protocols, regulatory compliance, and documented safety records.
Expert Perspective: Dr. Neil Riordan
Dr. Neil Riordan, founder of the Stem Cell Institute in Panama, has been at the forefront of UC-MSC research and clinical application since 2007. With over 15 years of experience treating thousands of patients, his insights on autoimmune conditions are particularly noteworthy:
Clinical Insights on Treatment Outcomes
Rheumatoid Arthritis: “Almost everybody gets better and with one treatment they don’t have to come back… I love that disease” – Dr. Riordan notes this is among the most responsive conditions to UC-MSC therapy.
Multiple Sclerosis: Response varies based on disease progression. Relapsing-remitting MS typically responds better than secondary progressive disease. Some patients require periodic retreatment while others achieve long-term remission.
Hashimoto’s Thyroiditis: Several cases achieved remission with single treatment; others required multiple treatments depending on disease severity and duration.
Heart Failure: Specific types of heart failure respond remarkably well, often “one and done” treatments with sustained improvement.
Food Intolerances: Documented cases of severe food sensitivities resolving after UC-MSC treatment, including patients restricted to only 3 foods returning to normal diets years after treatment.
Additional Research Resources
For those interested in diving deeper into the scientific literature, the following resources provide comprehensive information:
- ClinicalTrials.gov: Search “umbilical cord mesenchymal stem cells” to find ongoing and completed clinical trials
- PubMed/NCBI: Access to full database of published medical research on MSCs and regenerative medicine
- Dr. Riordan’s Book: “Stem Cell Therapy: A Rising Tide” provides accessible education on stem cell therapy for general audiences
Interested in Learning More?
Our team is available to discuss your specific condition and whether UC-MSC therapy might be appropriate for you. Schedule a consultation to review your medical history with our physicians.
Schedule Consultation